245 related articles for article (PubMed ID: 8917560)
1. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.
Balzarini J; Pelemans H; Karlsson A; De ClercQ E; Kleim JP
Proc Natl Acad Sci U S A; 1996 Nov; 93(23):13152-7. PubMed ID: 8917560
[TBL] [Abstract][Full Text] [Related]
2. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
3. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
[TBL] [Abstract][Full Text] [Related]
4. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
Balzarini J; Pelemans H; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
Mol Pharmacol; 1996 May; 49(5):882-90. PubMed ID: 8622638
[TBL] [Abstract][Full Text] [Related]
5. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.
Balzarini J; Weeger M; Camarasa MJ; De Clercq E; Uberla K
Biochem Biophys Res Commun; 1995 Jun; 211(3):850-6. PubMed ID: 7541200
[TBL] [Abstract][Full Text] [Related]
8. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
Nitanda T; Wang X; Somekawa K; Yuasa S; Baba M
Antivir Chem Chemother; 2001 May; 12(3):161-7. PubMed ID: 12959324
[TBL] [Abstract][Full Text] [Related]
9. Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1.
Jonckheere H; Witvrouw M; De Clercq E; Anné J
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):249-53. PubMed ID: 9491915
[TBL] [Abstract][Full Text] [Related]
10. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
11. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.
Kleim JP; Rösner M; Winkler I; Paessens A; Kirsch R; Hsiou Y; Arnold E; Riess G
Proc Natl Acad Sci U S A; 1996 Jan; 93(1):34-8. PubMed ID: 8552634
[TBL] [Abstract][Full Text] [Related]
12. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
[TBL] [Abstract][Full Text] [Related]
13. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.
Van Laethem K; Witvrouw M; Pannecouque C; Van Remoortel B; Schmit JC; Esnouf R; Kleim JP; Balzarini J; Desmyter J; De Clercq E; Vandamme AM
AIDS; 2001 Mar; 15(5):553-61. PubMed ID: 11316991
[TBL] [Abstract][Full Text] [Related]
15. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
Smith SJ; Pauly GT; Akram A; Melody K; Ambrose Z; Schneider JP; Hughes SH
J Acquir Immune Defic Syndr; 2016 Aug; 72(5):485-91. PubMed ID: 27124362
[TBL] [Abstract][Full Text] [Related]
16. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
[TBL] [Abstract][Full Text] [Related]
18. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
[TBL] [Abstract][Full Text] [Related]
19. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
[TBL] [Abstract][Full Text] [Related]
20. The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase.
Rezende LF; Drosopoulos WC; Prasad VR
Nucleic Acids Res; 1998 Jun; 26(12):3066-72. PubMed ID: 9611256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
